Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-22-024162
Filing Date
2022-11-10
Accepted
2022-11-10 07:31:50
Documents
94
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q atai-20220930.htm   iXBRL 10-Q 6947874
2 EX-10.2 atai-ex10_2.htm EX-10.2 830622
3 EX-31.1 atai-ex31_1.htm EX-31.1 18693
4 EX-31.2 atai-ex31_2.htm EX-31.2 21069
5 EX-32.1 atai-ex32_1.htm EX-32.1 12306
6 EX-32.2 atai-ex32_2.htm EX-32.2 12354
7 GRAPHIC img105020950_0.jpg GRAPHIC 92815
8 GRAPHIC img194914858_0.jpg GRAPHIC 48167
  Complete submission text file 0000950170-22-024162.txt   28361832

Data Files

Seq Description Document Type Size
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT atai-20220930_lab.xml EX-101.LAB 1029748
10 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT atai-20220930_def.xml EX-101.DEF 695545
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT atai-20220930_pre.xml EX-101.PRE 900552
12 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT atai-20220930.xsd EX-101.SCH 152648
13 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT atai-20220930_cal.xml EX-101.CAL 79451
88 EXTRACTED XBRL INSTANCE DOCUMENT atai-20220930_htm.xml XML 6807266
Mailing Address 524 BROADWAY NEW YORK NY 10013
Business Address WALLSTRASSE 16 BERLIN 2M 10179 (617)-699-5876
ATAI Life Sciences N.V. (Filer) CIK: 0001840904 (see all company filings)

EIN.: 000000000 | State of Incorp.: P7 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40493 | Film No.: 221374954
SIC: 2834 Pharmaceutical Preparations